LYCA
Lycia Therapeutics, Inc.
Set alert
- YTD
- -12.00%
- 1 year
- -12.00%
- Open
- 26.28
- Prev close
- 27.73
- Mkt cap
- 1.38B
- Vol
- 202.45K
- Avg vol
- 856.50K
- EPS
- -1.04
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 25.66
- High
- 27.59
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 39.24%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 27.55
- 200-d avg
- 27.55
- 1y target
- 0.00
Key statistics
- Market cap
- 1.38B
- Enterprise value
- 562.15M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 310.10
- Price / book
- 0.00
- EPS (TTM)
- -1.04
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 4.43M
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 124.32M
- Total debt
- 3.16M
- Return on equity
- 0.00%
- Shares outstanding
- 52.09M
- Short % of float
- 0.00%
- 50-day average
- 27.55
- 200-day average
- 27.55
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy. The company also develops LCA-0062, a follow-on program designed to degrade IgE for the treatment of allergic diseases. Additionally, it develops LCA-0321, a candidate designed to selectively degrade TSHR autoantibodies (thyrotropin receptor antibodies, or TRAbs), the pathogenic drivers of Graves' disease. Lycia Therapeutics, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lyciatx.com
News
- Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere
- U.S. IPO Weekly Recap: Trickle Of Biotech Activity Continues Amid Tech Sell-Off
- Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering
- Drug developer Lycia Therapeutics targets $938 million valuation in US IPO
Your note
Sign in to keep a note on LYCA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 26, 2026 | 0 |